Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

35.78 -1.94 (-5.14%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts ↗
The company reported that complete skin clearance rates increased twofold to fivefold during the maintenance phase of the trial. 
Via Stocktwits
Top stock movements in today's session. ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin. 
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗
There is a key difference between these two biotechs. 
Via The Motley Fool
Topics Bankruptcy
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Shares in the biotech company have surged on news of a big pharma takeover. 
Via The Motley Fool
News headline image
Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Top Estimates, Sending Shares Higher ↗
Nektar Therapeutics (NKTR) Q3 2025 results beat analyst estimates for both revenue and earnings per share, sending the stock higher in after-hours trading. 
Via Chartmill
News headline image
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street ↗
Is it too late to get on the bandwagon? 
Via The Motley Fool
News headline image
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September ↗
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗
Here's what needs to happen for these high flyers to continue soaring. 
Via The Motley Fool
News headline image
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today ↗
One of the company's pipeline drugs is showing significant promise. 
Via The Motley Fool
News headline image
Why Is Nektar Therapeutics Stock Trading Lower On Thursday? ↗
Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients. 
Via Benzinga
News headline image
Why Nektar Therapeutics Rippled Higher This Week ↗
The company's competitive positioning might be stronger now, after disappointing results from a key rival. 
Via The Motley Fool
Topics Intellectual Property
News headline image
What's Going On With Nektar Therapeutics Stock On Thursday? ↗
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Why Nektar Therapeutics Stock Popped 6% on Friday ↗
The company said it has sufficient financial resources to fund its operations into early 2027. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.